![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » AbbVie Submits NDA for Uterine Fibroid Drug
AbbVie Submits NDA for Uterine Fibroid Drug
![AbbVie logo](https://www.fdanews.com/ext/resources/test/Drug-Images2/abbvie.gif?t=1624653675&width=430)
August 6, 2019
AbbVie has filed a new drug application for Orilissa (elagolix), a medication for managing heavy menstrual bleeding caused by uterine fibroids.
The application for the oral gonadotropin-releasing hormone (GnRH) antagonist is bolstered by data from a Phase 3 uterine fibroid trial, which evaluated nearly 800 premenopausal women with heavy menstrual bleeding associated with uterine fibroids in two pivotal studies.
Uterine fibroids are non-cancerous tumors found in muscle tissue. While they can be asymptomatic, in some patients they can cause vaginal bleeding, heavy menstrual bleeding and anemia, among other symptoms.
Upcoming Events
-
21Oct